期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞发育异常——MDS诊断关键之所在 被引量：4

原文传递
导出
摘要 骨髓增生异常综合征（MDS）是一组起源于造血干细胞的恶性克隆性疾病，其基本病理生理改变是造血干细胞和（或）祖细胞发育异常及无效造血，其临床特征为一系或多系血细胞减少、骨髓和（或）外周血细胞有发育异常的形态学表现、最终发展为急性白血病或骨髓衰竭。
作者 刘新月
机构地区 华中科技大学同济医学院附属协和医院血液病研究所
出处 《临床血液学杂志》 CAS 2011年第6期642-644,648,共4页 Journal of Clinical Hematology
关键词 骨髓增生异常综合征 细胞形态 发育异常 诊断
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献6

  • 1BENNETT J M, CATOVSKY D, DANIEL M T, et al. Proposals for the classification of the myelodysplastic syndromes[J].Br J Haematol ,1982,51:189 --199.
  • 2VARDIMAN J W, HARRIS N I., BRUNNING R D The World Health Organization (WHO) classifica tion of the myeloid neoplasms[J]. Blood, 2002,100 :2292 -2302.
  • 3VARDIMAN J W, THIELE J, ARBER D A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [J]. Blood, 2009,114:937--951.
  • 4MUFTI G J, BENNETT J M, GOASGUEN J, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts[J]. Haematologica, 2008,93:1712--1717.
  • 5CANTO RAJNOLDI A, FENU S, KERNI)RUP G, et al. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS) [J]. Ann Hematol, 2005, 84..429--433.
  • 6VALENT P, HORNY H P, BENNETT J M, et al. Definitions and standards in the diagnosis and treat ment of the myelodysplastic syndromes: consensus statements and report from a working conference[J]. Leuk Res, 2007,31:727--736.

同被引文献31

  • 1肖志坚.循证医学指导下的血液病规范化诊治[J].中国实用内科杂志,2007,27(14):1091-1094. 被引量：18
  • 2BRUNNING R D, A O, GERMING U,et al. Myelo-dysplastic syndromes/Neoplasms, overview [ M ]//SWERDLOW S H.CAMPO E, HARRIS N L,et al.WHO classification of tumours of haematopoietic andlymphoid tissues. Lyon: I ARC, 2008 : 88 -93.
  • 3MARISAVLJEVIC DXEMERIKIC V,ROLOVIC Z,et al. Hypocellular myelodysplastic syndromes : clinicaland biological significance [J]. Med Oncol,2005,22 :169-175.
  • 4SCHECTER J,GALIU N’RAZA A. MDS: Refiningexisting therapy through improved biologic insights[J]. Blood Rev,2012,26 :73 -80.
  • 5PASSWEG J R,GIAGOUNIDIS A A,SIMCOCK M,et al. Immunosuppressive therapy for patients withmyelodysplastic syndrome: A prospective randomizedmulticenter phase E trial compareing antithymocyteglobulin plus cyclosporine with best supportive care-sakk33/99[J]. J Clin Oncol,2011,29 :313-319.
  • 6Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ]. Lyon, France : IARC ,2008.
  • 7Tomonaga M. Nuclear abnormaliiies in Pelger-Huet anomaly : pro- gress in blood cell morphology[ J]. Rinsho Byori,2005,53 (1) : 54-60.
  • 8中华医学会血液学分会实验诊断血液学学组.血细胞形态学分析中国专家共识(2013年版)[J]中华血液学杂志,2013,34:73-74.
  • 9Matsushima T,Handa H,Yokohama A,et al.Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia[J].Blood,2003,101:3386-3390.
  • 10Nolte F,Hofmann WK.Molecular mechanisms involved in the progression of myelodysplastic syndrome[J].Future Oncol,2010,6:445-455.

引证文献4

二级引证文献9

临床血液学杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部